Vivek Subbiah: The evolving landscape of tissue-agnostic therapies in precision oncology

Vivek Subbiah recently shared the following insight on LinkedIn:

“HOT OFF THE PRESS

Just in time for the American Society of Clinical Oncology (ASCO) annual meeting.

Published in the highest impact factor journal in all of oncology CA: A Cancer Journal for Clinicians – A flagship journal of the American Cancer Society.

Such a delight to share with the world in open access for all to read. The evolving landscape of tissue-agnostic therapies in precision oncology.”

Read further
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor-agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.